Case Report| Volume 16, ISSUE 12, P1698-1699, December 2009

Download started.


Detection of MCP-1 and IL-8 in the serum and cerebrospinal fluid of a child with Miller Fisher syndrome


      We describe an 11-year-old female patient who presented with a 7-day history of diplopia and difficulty walking. On examination she had ataxia, areflexia and ophthalmoplegia, and a diagnosis of Miller Fisher syndrome (MFS) was made after the exclusion of other conditions. Monocyte chemotactic protein-1 (MCP-1) and interleukin (IL)-8 chemokine levels in the cerebrospinal fluid (CSF) were significantly increased in the acute phase. We believe MFS in this patient was due to both peripheral nervous system dysfunction, and central nervous system (CNS) involvement. The cause of MFS in this patient was suggested by the localized chemokine production in the CSF. The high expression of MCP-1 and IL-8 chemokines suggest that macrophages and T cells may stimulate inflammation of the CNS in MFS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fisher C.M.
        An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia).
        N Engl J Med. 1956; 255: 57-65
        • Jamal G.A.
        • Ballantyne J.P.
        The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome). A serial multimodal neurophysiological study.
        Brain. 1988; 111: 95-1143
        • Berlit P.
        • Rakicky J.
        The Miller Fisher syndrome, review of the literature.
        J Clin Neuroophthalmol. 1992; 12: 57-63
        • Toshniwal P.
        Demyelinating optic neuropathy with Miller-Fisher syndrome. The case for overlap syndromes with central and peripheral demyelination.
        J Neurol. 1987; 234: 353-358
        • Hughes R.A.
        • Rees J.H.
        Clinical and epidemiologic features of Guillain-Barré syndrome.
        J Infect Dis. 1997; 176: 92-98
        • Lyu R.K.
        • Tang L.M.
        • Cheng S.Y.
        • et al.
        Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients.
        J Neurol Neurosurg Psychiatry. 1997; 63: 494-500
        • Mori M.
        • Kuwabara S.
        • Fukutake T.
        • et al.
        Clinical features and prognosis of Miller Fisher syndrome.
        Neurology. 2001; 56: 1104-1106
        • Koga M.
        • Yuki N.
        • Takahashi M.
        • et al.
        Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain–Barre´ and Fisher’s syndrome.
        J Neuroimmunol. 1998; 81: 138-143
        • Prineas J.W.
        Pathology of inflammatory demyelinating neuropathies.
        Baillieres Clin Neurol. 1994; 3: 1-24
        • Schmidt B.
        • Toyka K.V.
        • Kiefer R.
        • et al.
        Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy.
        Muscle Nerve. 1996; 19: 474-487
        • Hughes R.A.
        Pathogenesis and treatment of inflammatory demyelinating polyradiculoneuropathy.
        Acta Neurol Belg. 2000; 100: 167-170
        • Press R.
        • Pashenkov M.
        • Jin J.P.
        • et al.
        Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
        J Clin Immunol. 2003; 23: 259-267
        • Lund B.T.
        • Ashikian N.
        • Ta H.Q.
        • et al.
        Increased CXCL8 (IL-8) expression in multiple sclerosis.
        J Neuroimmunol. 2004; 155: 161-171